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ABSTRACT 
Objectives: To evaluate the impact of a safety warning on the utilization rates of 
thiazolidinedione oral anti-diabetes medication using an interrupted time series analysis. 
Methods: We extracted data from a five percent national sample of Medicare Part D 
beneficiaries for the periods between January 2006 and December 2008. Beneficiaries with Part 
D claims for thiazolidinediones were classified into appropriate-use, at risk, and contraindicated 
groups based on certain comorbid conditions. We assessed the effects of the May 2007 FDA 
safety warning about an ongoing safety review of rosiglitazone’s potential to increase 
cardiovascular risks on thiazolidinedione utilization rates using an interrupted time series 
consisting of 32 data points (13 months before and 19 months after the safety warning).  
Results: There was an increasing trend in the total utilization rates of thiazolidinediones before 
the safety warning. Significant decline in drug utilization rates were observed at the end of the 
study period for all patient groups on rosiglitazone (relative difference -74.78%, -79.93%, and -
90.21% respectively in appropriate-use, at risk and contraindicated patient groups). The 
intervention did not have significant immediate effects on the post-intervention utilization rates 
of pioglitazone. However, after the intervention, we observed a general decline in utilization of 
thiazolidinediones. 
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Conclusions: The initial safety warning about rosiglitazone’s cardiovascular safety was effective 
in decreasing rosiglitazone’s utilization in the targeted population and hence its Medicare market 
share. The safety warning also had spillover effects by reducing utilization of drugs in other 
patient cohorts not targeted by the warning. 
Key Words: Interrupted time series, Safety-warning, Rosiglitazone, Pioglitazone, Market 
response. 
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CHAPTER I 
INTRODUCTION 
Patients in the U.S. have access to the safest and most advanced pharmaceutical system in 
the world.1 Drugs produced for U.S. markets are subjected to perhaps the most rigorous drug 
approval process.2 The aim of this drug approval process, conducted by the Food and Drug 
Administration (FDA), is to demonstrate that drugs seeking approval are safe and effective for 
their indicated use. Safe in this regard means that the benefits associated with the use of a drug 
outweighs its risk of use.1  
The FDA is responsible for protecting public health by ensuring that drugs, vaccines, and 
other biological products and medical devices intended for human use are safe and effective. The 
FDA also shares with pharmaceutical companies, physicians, and pharmacists, the responsibility 
of helping the public get accurate science-based information required for proper use of medicines 
and devices.3 The FDA achieves the former role through a rigorous drug approval process and 
postmarketing surveillance. Communicating important safety information regarding drug use is 
achieved via FDA safety newsletters and the “MedWatch” program - a web-based resource that 
provides specific information relating to drugs that have been the subject of a public health 
advisory or an alert.4,5  
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The effectiveness of FDA’s postmarketing surveillance system can be attributed to key 
tasks performed during this surveillance period. These tasks include detecting post-approval 
safety issues and communicating these to the public. Detection of post-approval safety issues 
occur either during post-marketing clinical/phase IV trials conducted by pharmaceutical 
companies or through FDA’s adverse event reporting system (AERS) and MedWatch. Medwatch 
also serves as an effective avenue for communicating safety information to the medical 
community. Following the evaluation of new safety information, the FDA provides postmarket 
drug safety information to patients and providers. The FDA also issues safety alerts, enforces 
labeling changes, and/or restricts access to drugs when appropriate. These actions could 
potentially affect treatment and diagnostic options for both healthcare professionals and patients. 
4, 12 
The Black box warning, a type of safety warning and a marker of the most serious 
adverse drug reactions (ADRs),7 prompts actionable changes in clinical use of a drug without 
necessarily requiring an immediate market withdrawal. The overall effects of safety warnings on 
prescribing habits have prompted studies to evaluate the intended and unintended consequences 
of such warnings8,9 as well as the adequacy of these warnings in restricting use of unsafe 
drugs.10,11 
The body of research that has focused on the use of thiazolidinediones in the management 
of type II diabetes demonstrates opposing views on the direction of prescription trends and 
promptness of the medical community in adhering to black box warnings.  One of these studies10 
evaluated the utilization of rosiglitazone following black box warnings and found that 
geographic variations coupled with a modest decline in the number of prescriptions written for 
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rosiglitazone does exist. Another study11 which evaluated the utilization of troglitazone in 
response to black box warnings found that initial safety warnings were ineffective in prompting 
actionable changes. 
These studies establish conflicting evidence on the changes in the number of 
prescriptions for the thiazolidinediones class of drugs following FDA safety warnings. Thus, 
adequate evidence to infer a logical conclusion on the actual market response to FDA safety 
warnings for drugs in the thiazolidinedione class of oral hypoglycemic agents is lacking. An 
appropriate market response to FDA safety warnings is critical in order to assure reasonable 
safety in the health care system, as well as to protect the drug development investment made by 
the pharmaceutical product manufacturer. The purpose of this study is to investigate the 
appropriateness of market response to the FDA black box warning issued for rosiglitazone. This 
study will use an interrupted time series design to determine whether changes in product use are 
differentiated by appropriate and inappropriate patient types. 
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CHAPTER II 
LITERATURE REVIEW 
Diabetes Mellitus: Prevalence and Cardiovascular Risks 
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both.12 About 15.3% of American 
adults 65 years or above have been diagnosed with DM.13 Management of DM involves a 
multifaceted approach that includes pharmacological therapy and life-style changes. One of the 
pharmacological interventions for the management of diabetes mellitus are the thiazolidinedione 
class of oral hypoglycemic agents which were first introduced to the U.S. market in 1997.16  
Historical Overview of Rosiglitazone-specific FDA warnings 
Troglitazone (Rezulin®; Parke-Davis/Warner-Lambert), Rosiglitazone (Avandia®; 
GlaxoSmithKline), and Pioglitazone (Actos®; Takeda), drugs belonging to the anti-diabetic class 
of thiazolidinediones (TZDs), have received numerous safety alerts and labeling change 
recommendations from the FDA in order to ensure their safe use. Troglitazone was withdrawn 
from the U.S. market on March 21, 2000 because of its adverse hepatic effects.17 Rosiglitazone 
and pioglitazone are still available in the U.S. market. However, their future market potential 
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remains uncertain because varied metabolic effects in addition to their hypoglycemic effects 
have stirred doubts about their cardiovascular safety.16   
In 2007, new safety information on the cardiovascular risks of rosiglitazone was made 
available by the FDA15, 16 following a meta-analysis of 42 trials comparing rosiglitazone to 
placebo. These studies demonstrated that rosiglitazone was associated with an increased risk of 
myocardial infarction and death from cardiovascular sources.18 This disclosure engendered a 
series of empirical inquiries into the safety of rosiglitazone and its utility in managing Type 2 
diabetes mellitus.20,21  
Rosiglitazone was first approved by the FDA in May 1999 as an adjunct to diet and 
exercise to improve glycemic control in patients with Type 2 diabetes mellitus.22 On the 21st of 
May 2007, FDA issued a safety alert to inform healthcare professionals and the public about an 
ongoing safety review of rosiglitazone’s potential to increase cardiovascular risks.18, 19 By 
August 2007, a boxed warning to include an increased risk of new onset or exacerbations of 
congestive heart failure (CHF) was approved for rosiglitazone. In November 2007, another 
boxed warning about an increased potential for heart failure was added to rosiglitazone’s 
labeling.25 More recently, in September 2010, the FDA decided to significantly restrict access to 
rosiglitazone use.26 
The period between the first alert and the end of 2007 could safely be assumed as an 
adequate period of awareness to the safety issues expressed with rosiglitazone use. In addition, 
the boxed warnings issued during that year were expected to prompt careful consideration on the 
part of prescribing physicians. A stream of research has however demonstrated poor adherence to 
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FDA alerts and warnings regarding the use of rosiglitazone and other classes of drugs, often 
leaving patients exposed to potentially harmful drugs.8-11 
Response to FDA Safety Warnings 
The body of literature on the utilization of thiazolidinedione in response to FDA safety 
alerts demonstrates conflicting evidence with regards to the adequacy of safety warnings in 
limiting utilization of implicated drugs. Wilkinson et al.,11 demonstrated that initial safety alerts 
issued for cisapride and troglitazone were inadequate in preventing the use of these drugs in at 
risk patients. Their study found that contraindicated use of cisapride was not significantly 
reduced by the issuance of “Dear healthcare professional” letters and labeling changes; rather, 
there was a significant increase in the number of new and total prescriptions for cisapride five 
months after the first alert with growth in total and new prescriptions declining only after the 
third alert. A similar trend was observed with troglitazone - the total number of prescriptions 
maintained an upward trend after the first three alerts, decreasing only after the fourth alert. Total 
number of new prescriptions however began to decline after the second alert. 
Shah et al.,10 found geographical variations in the use of rosiglitazone following FDA 
warnings. Despite these variations, their study demonstrated a significant decline in the total 
number of rosiglitazone prescriptions across the U.S. Their study also showed that FDA 
warnings can be interpreted differently across prescribing physicians, resulting in inconsistent 
patient protection from unsafe drug use. In their discussion, Shah et al. posit that the variations in 
prescriptions may be influenced by specialists, key opinion leaders and pharmaceutical 
marketing activities.  
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Intended and Unintended consequences of FDA Safety Warnings 
Katz et al.,8 examined the relationship between prescriptions rates of anti-depressants and 
FDA regulatory warnings in two groups. One of the groups which was not the focus of the 
warning served as a “control” group. The prescribing rate in this control group was thus expected 
to remain fairly constant. Their study however observed a significant decrease in prescriptions 
rate of anti-depressants for both groups, including the group not targeted by the alerts. In 
addition, there were no significant differences in prescription rates for both groups. The 
implication of their findings was that FDA warnings may have similar effect in reducing 
prescribing rates, and hence utilization of other drugs in the same therapeutic class as drug(s) 
targeted by warnings.  
In another study, Libby et al.9 observed significant and persistent declines in anti-
depressant prescriptions for both targeted and untargeted cohorts despite an absence of a 
complementary increase in prescriptions for anti-depressant alternatives such as anxiolytics and 
atypical psychotics. This finding is indicative of a general decline in depression treatment and a 
general decrease in case findings of depression among their study population. 
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Study purpose 
Geographical variations in market behaviors and evidence supporting a general decline in 
the use of rosiglitazone indicate that market response to safety warnings may not be limited to 
the targeted population. Further, the indiscriminate restriction in the use of a drug raises the 
question of whether a market, in this case comprised of health professionals and patients, 
appropriately responds to FDA safety warnings. This study examined changes in the utilization 
rates of rosiglitazone and pioglitazone during the periods before and after the May 2007 FDA 
safety warning for rosiglitazone in the following three patient groups (see Table I): 
• Patients for whom the use of rosiglitazone was considered appropriate (Appropriate-use 
group), 
• Patients with a medical history of heart failure and/or myocardial infarction, considered 
to be contraindicated for rosiglitazone use (Contraindicated group), and  
• Patients deemed at risk of developing contraindicated condition(s), due to rosiglitazone 
use, by virtue of the presence of an identifiable medical condition considered to be risk 
factors for heart failure and myocardial infarction (At risk group). These identifiable risk 
factors included hypertension, coronary artery disease and metabolic syndrome.  
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Study objectives 
The major objective was to assess the appropriateness in the utilization and/or declining 
use of rosiglitazone after May 2007. We also examined the changes in the utilization of 
pioglitazone (a drug in the thiazolidinedione class but not targeted by the warning) in order to 
determine the “class effect” of the rosiglitazone safety warning. 
We utilized an interrupted time series design to evaluate the longitudinal effects of an 
intervention, that is, an FDA safety warning, on rosiglitazone use in a national sample of the 
Medicare population. We obtained monthly utilization rates for rosiglitazone and pioglitazone 
during the period preceding and following the May 2007 safety warning in order to determine 
the effects of the safety warning on thiazolidinedione utilization. To the best of our knowledge, 
no study to date has attempted to examine the effects of FDA safety warnings specific to 
rosiglitazone by comparing the utilization rates in the population or groups being proposed. 
Thus, this study will contribute significantly to an understanding of the appropriateness of 
market response to FDA safety warnings.  
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CHAPTER III 
METHODS 
The study was approved by the Institutional Review Board (IRB) of the University of 
Mississippi. 
Study population 
The study population consisted of all beneficiaries who were continuously enrolled in 
Medicare Part D during the study period beginning from 1st of January, 2006 through 31st of 
December, 2008. The study inclusion and exclusion criteria are described below: 
Inclusion Criteria 
Medicare part D beneficiaries with at least one prescription claim for a thiazolidinedione 
anti-diabetic during the study period were included in the study. The eligible beneficiaries were 
identified from the part D event file as all beneficiaries with at least one claim for a 
thiazolidinedione anti-diabetic during the study period. This group served as the denominator for 
examining use of thiazolidinediones throughout the observation period. A total of 57,329 
beneficiaries were included in the analysis. 
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Exclusion Criteria 
The following exclusion criteria were used for this study: 
1. Medicare part D beneficiaries who were in skilled nursing facilities,  
2. Medicare beneficiaries who had end stage renal disease (ESRD), 
3. Medicare beneficiaries who had Medicaid dual eligibility, or 
4. Medicare beneficiaries enrolled in Medicare Advantage programs 
Data Sources 
The data set used for this study was the five percent national Medicare sample from the 
Center for Medicare and Medicaid Services (CMS).  Use of this data was covered by a data use 
agreement with CMS. The Medicare program is made up of Part A - hospital insurance, Part B - 
supplementary medical insurance (SMI), Part C - Managed care, and Part D - outpatient 
prescription benefits. 
The Medicare research identifiable files used for this study consisted of a denominator 
file and claims files.  
The denominator file contained the following information: 
• Information on patient enrollment,   
• Demographic information, and  
• Other beneficiary level data.  
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The first four months of available data (January 2006 to April 2006) served as an initial 
patient classification period (Figure 1). During this period, eligible beneficiaries were classified 
into appropriate-use, at-risk and contraindicated groups based on appropriateness for using 
thiazolidinediones. Following this initial classification period, beneficiaries were re-classified as 
appropriate each month throughout the remainder of the study period.  
ICD-9 diagnosis codes from medical office visits (carrier claim files), patient files (MEDPAR), 
and institutional outpatient visits (outpatient files) were used to classify beneficiaries into 
respective groups. Once beneficiaries were classified into a group, it was assumed that they 
remained in that group until the end of the study unless they were re-classified into another group 
with higher contraindication severity. The groups were ranked in contraindication severity in the 
following order: 
Appropriate-use < At risk < Contraindicated 
Table 1 lists the diagnostic criteria used for group classification (‘x’ was used as an 
indicator of diseases/conditions belonging to respective groups). These classification criteria 
were based on the November 2007 FDA safety warning issued for rosiglitazone25. According to 
this safety warning, rosiglitazone is contraindicated in patients with any of the following 
conditions: NYHA class III or IV heart failure, symptomatic heart failure, congestive heart 
failure or myocardial infarction. We also included diagnosis codes for old myocardial infarction 
(412.xx) in order to adequately identify and classify patients who have had a myocardial 
infarction before our study initiation period.  
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Table I. Group Classification Criteria 
DISEASE/CONDITION  ICD9 CODES  PATIENT GROUP  
APPROPRIATE-
USE  
AT 
RISK  
CONTRAINDICATED 
HYPERTENSION  401.XX, 405.XX   X  
CORONARY ARTERY 
DISEASE  
440.XX, 414.XX   X  
OVERWEIGHT & OBESITY  278, 278.00, 278.01, 
278.02  
 X  
METABOLIC SYNDROME  277.7   X  
HEART FAILURE  402.X1, 404.X3, 428.XX   X 
OLD MYOCARDIAL 
INFARCTION  
412.XX    X 
MYOCARDIAL 
INFARCTION  
410.XX    X 
 
The at-risk patients were identified as patients with identifiable medical conditions (i.e. 
conditions with ICD-9 codes) considered as risk factors for developing any of the 
contraindicated diseases/conditions mentioned above.14, 27 In addition, metabolic syndrome was 
included to represent a cluster of other risk factors. These risk factors include overweight, high 
lipids and diabetes mellitus. The appropriate-use patients were identified as all other patients 
meeting the inclusion criteria but without a medical diagnosis for any of the above 
diseases/conditions.  
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Rationale for selecting rosiglitazone (Avandia ®) 
Safety warnings are markers of potentially serious adverse effects of drug use. These 
warnings, which are not frequently issued, have the potential to alter clinical use of implicated 
drugs often resulting in intended and unintended effects of such warnings. Some of these effects 
include an overly restricted use of implicated drugs in populations not targeted by these 
warnings.  
In order to examine the effects of safety warnings or any intervention, adequate time points 
before and after the intervention are required. The availability of retrospective Medicare data 
(January 2006 to December 2008) having adequate time points pre and post the safety warnings 
for rosiglitazone in May 2007, allows the study of these intended and unintended effects of 
safety warnings. Moreover, the variations in rosiglitazone use reported prompts further 
investigation into market response to rosiglitazone specific safety warnings. 
Evaluation of the safety warning (Intervention) 
Time series of thiazolidinedione utilization within each patient group were constructed as 
a rate by dividing the number of beneficiaries taking thiazolidinediones in each group per month 
by the number of beneficiaries classified as belonging in the group that month. The resulting 
time series were analyzed by specifying a segmented regression model.  
Segmented regression analysis of interrupted time series enables estimation of, in 
statistical terms, changes in the level and trend in an outcome of interest immediately and over 
time following an intervention28. This is achieved by fitting the observations into an adequate 
regression model. The outcome of interest in this study was the utilization rates (per 100) of both 
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rosiglitazone and pioglitazone in all patient groups before and after the safety warning. 
Following the visual inspection of the plot of the monthly utilization of thiazolidinedione in each 
group against time, segmented regression models (Model 1) were specified using the general 
linear models procedure (proc glm) for SAS in order to determine the effects of the intervention 
while assessing the effect of chance and controlling for other confounders. Initial models were 
examined for the presence of autocorrelation in error terms using the Durbin-Watson test for 
autocorrelation. When the Durbin-Watson test statistic was significant, indicating presence of 
autocorrelation, we included the estimated autocorrelation parameter in the model. Segmented 
regression models were further examined for significance of parameter estimates, eliminating 
insignificant variables when appropriate, by means of a backward elimination method. The 
resulting parsimonious models were then re-specified. All analyses and data management were 
carried out using SAS 9.2. 
Model 1 shows the full segmented regression equation for estimating the level and trend 
in the utilization rates of thiazolidinediones in each class of patients before and after the 
rosiglitazone FDA safety warning: 
ܴܽݐ݁௧ ൌ  ߚ଴ ൅ ߚଵ כ  ݐ݅݉݁௧ ൅ ߚଶ כ ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊௧ ൅ ߚଷ כ ݐ݅݉݁ ݂ܽݐ݁ݎ ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊௧ ൅ ݁௧ (Model 1)  
Where: 
• ܴܽݐ݁௧ is the utilization rate of thiazolidinediones anti-diabetic drugs in month t 
• ݐ݅݉݁ is a continuous variable indicating the time in months from the beginning of the 
observation period 
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• ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ is an indicator for time t occurring before (intervention = 0) or after 
(intervention = 1) the safety warning 
• ݐ݅݉݁ ݂ܽݐ݁ݎ ݅݊ݐ݁ݎݒ݁݊ݐ݅݋݊ is a continuous variable counting the number of months after 
the intervention at time t 
• ߚ଴ estimates the baseline level of the claims rate at the beginning of the study period (at 
time zero) 
• ߚଵ estimates the change in claims rates that occurs with each month before the 
intervention (i.e the baseline trend) 
• ߚଶ estimates the level change in the rate of claims for thiazolidinediones anti-diabetic 
drugs immediately after the intervention 
• ߚଷ estimates the change in trend in the mean monthly rate of claims for 
thiazolidinediones anti-diabetic drugs per month after the safety warning, compared with 
monthly trend before the safety warning.
 18 
 
CHAPTER IV 
RESULTS 
Population Characteristics 
The total population for this study following the application of the inclusion and 
exclusion criteria was 57,329. Their demographic characteristics are represented in Table II. 
Women constituted 54.7% of the study population. Eighty-four percent of the beneficiaries were 
white, 10% were black and 6% were of other races (Asian, Hispanic, North American Native and 
others). Forty-seven percent of the population were between the ages of 65 and 74, 34% were 
between the ages of 75-84, 11% were older than 85 years of age while less than 5% were 
younger than 65 years old. 
Table II: Study Population Demography 
 Demographic Variables  Percentage  
Gender  Female  54.7  
Male  45.3  
Race  White  84  
Black  10  
Other  6  
Age  < 65 years  5  
65 – 74 years  47  
75 – 84 years  37  
> 85 years  11  
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Time Series of Thiazolidinedione Utilization 
The interrupted time series consisted of 32 data points divided into 2 segments by the 
FDA safety warning for rosiglitazone (intervention). Thirteen months of data were available 
prior to the intervention and 19 months of follow up data were available after the intervention for 
all beneficiaries. The rate of drug utilization was expressed as a monthly percentage of the 
number of patients in each sub-group. This percentage utilization was obtained for each month 
during the study period by dividing the number of patients classified into respective groups using 
a particular drug by the total number of patients classified into each group per month. For 
example, in the first month of our study period, 9204 patients classified as appropriate-use 
patients using rosiglitazone, while 8218 patients were classified as appropriate-use patients using 
pioglitazoone. During this month, the total number of patients classified as appropriate was 
47108. Hence the utilization rates for rosiglitazone and pioglitazone during this month were 
22.18% and 20.42% respectively. 
The effects of the intervention were expressed as changes in the level and trend of market 
utilization of thiazolidinedione as well as the relative effect of the intervention on 
thiazolidinedione utilization at the end of the study period (post-intervention month 19, study 
month 32) using the relative model (Model 2). A graph of the monthly utilization rates for all 
patient groups is shown in Figure 2. 
ܴܦ ൌ ሾ൫ ଷܻଶሺ௪௜௧௛ ௦௔௙௘௧௬ ௪௔௥௡௜௡௚ሻ െ ଷܻଶሺ௪௜௧௛௢௨௧ ௦௔௙௘௧௬ ௪௔௥௡௜௡௚ሻ൯/ ଷܻଶሺ௪௜௧௛௢௨௧ ௦௔௙௘௧௬ ௪௔௥௡௜௡௚ሻሿ כ 100 (Model 2) 
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Figure 2: Utilization rates of rosiglitazone and pioglitazone by patient group per month. 
 
The figure shows a slight increasing slope in the utilization rates for indicated and at risk 
patients taking rosiglitazone and pioglitazone before the intervention. However, following the 
intervention, there was an immediate, abrupt and consistent decline in the slope for all three 
groups of patients using rosiglitazone. For patients using pioglitazone, an increasing trend in 
slope was maintained for both indicated and at-risk patients while the slope for the 
contraindicated population in this patient population (using pioglitazone) gradually decreased 
after the intervention. 
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The time series were analyzed for the presence of serial autocorrelations between 
observations using the Durbin-Watson statistic. Significant autocorrelations were adjusted for by 
estimating the autocorrelation parameters for each model and including it in a final regression 
model. Table III shows the Durbin-Watson statistics for each regression model following 
correction for autocorrelation. 
Table III: Durbin-Watson statistics for group-specific regression models after controlling 
for autocorrelation. 
 
Drug Group  Regression Model  Durbin-Watson statistic Pr < DW  Pr > DW 
Rosiglitazone  Appropriate-use model 2.1069 0.4697 0.5303  
At-risk model  2.1914  0.6147  0.3853  
Contraindicated model 1.9234  0.2449  0.7551  
Pioglitazone  Appropriate-use model 1.7257  0.1076  0.8924  
At-risk model 1.6920  0.0922  0.9078  
Contraindicated model 1.8665  0.1768  0.8232  
Pr < DW is the P-value for hypothesis of positive correlation, and Pr > DW is the P-value for hypothesis of negative 
correlation 
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Effect of the FDA safety warning on rosiglitazone utilization in appropriate-use patients 
The results from Table IV indicate that just before the beginning of the observation 
period, the monthly utilization rate of rosiglitazone in the patient group classified as appropriate 
for rosiglitazone use was about 21 patients per 100 patients classified as appropriate patients for 
rosiglitazone use. Before the intervention, there was no significant month-to-month variation in 
rosiglitazone utilization (p-value = 0.679). Immediately after the intervention, the estimated 
utilization rate of rosiglitazone dropped by 2.4 patients per 100 patients. Following the 
intervention, there was a significant and consistent month-to-month decline of 0.87 patients per 
100 thiazolidinedione appropriate-use patients per month in comparison to the pre-intervention 
period. After stepwise elimination of non-significant terms, the most parsimonious model 
contained only the baseline trend in utilization, the immediate effect of the intervention, and the 
month-to-month variation in the utilization of rosiglitazone following the intervention (Table 
IVb). 
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Table IV: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models predicting the monthly utilization rate of 
rosiglitazone in appropriate-use patients. 
 
Variable Estimate Standard 
Error 
t-
statistic 
P-value 
a. Full segmented regression model     
Intercept 20.562 2.540 8.09 < 0.0001 
Time 0.117 0.280 0.42 0.6792 
Intervention -2.445 1.100 -2.22 0.0356 
Time after intervention -0.874 0.408 -2.14 0.0421 
b. Most parsimonious segmented 
regression model 
    
Intercept 21.506 1.173 18.33 < 0.0001 
Intervention -2.421 1.078 -2.25 0.0333 
Time after intervention -0.719 0.144 -5.01 < 0.0001 
 
Using the most parsimonious model (Table IVb), we estimated the relative change in 
utilization was -74.78%, indicating that rosiglitazone utilization rate in the appropriate-use 
patient group decreased by 74.78% at the end of the study period (month 32) compared to what it 
would have been in the same month had the safety warning not been issued. 
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Effect of the FDA safety warning on rosiglitazone utilization in patients at risk of 
developing contraindicated conditions 
In this patient population, the monthly utilization rate of rosiglitazone just before the 
beginning of the observation period was 19.95 patients per 100 patients classified as at-risk 
(Table V). Before the safety warning was issued, there was no significant month-to-month 
change in the percentage of patients using rosiglitazone (p-value = 0.646). There was also no 
significant change in the utilization rate of rosiglitazone (p-value = 0.693) and month-to-month 
utilization of rosiglitazone after the safety warning was issued (p-value = 0.078). After stepwise 
elimination of non-significant terms however, we observed a significant month-to-month 
decrease of less than 1 patient per 100 at-risk patients post-intervention in comparison to the pre-
intervention period (Table Vb). 
Table V: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models predicting the monthly utilization rate of 
rosiglitazone in patients at risk of developing contraindicated conditions. 
 
Variable  Estimate  Standard 
Error  
t-
statistic  
P-value 
a. Full segmented regression model     
Intercept  19.946  4.120  4.84  < 0.0001 
Time  0.204  0.439  0.47  0.646  
Intervention  0.398  0.998 0.40  0.693  
Time after intervention  -1.200  0.653  -1.86  0.078  
b. Most parsimonious segmented 
regression model 
    
Intercept 21.607 2.053 10.53 < 0.0001
Time after intervention -0.909 0.209 -4.53 < 0.0001
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From Table Vb, we estimated the relative change in utilization was -79.93%, indicating 
that rosiglitazone utilization in the at risk group decreased by 79.93% at the end of the study 
period (month 32) compared to what it would have been in the same month had the safety 
warning not been issued. 
 
Effect of the FDA safety warning on rosiglitazone utilization in patients contraindicated to 
use rosiglitazone 
The utilization rate in patients contraindicated for rosiglitazone use in the period just 
before the beginning of the observation was 19.43 patients per 100 contraindicated patients. 
Before the intervention, rosiglitazone use decreased at a rate of 0.49 patients per 100 
contraindicated patients. In the period immediately following the intervention, the rate of 
rosiglitazone use dropped abruptly by 4.62 patients per 100 contraindicated patients. There was 
however, no significant month-to-month change in rosiglitazone utilization after the safety 
warning (p-value = 0.6419) in comparison to the pre-intervention period (Table VIa).  
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Table VI: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models of the monthly utilization rate of rosiglitazone 
in contraindicated patients. 
 
Variable  Estimate Standard 
Error  
t-
statistic 
P-value  
a. Full segmented regression model     
Intercept  19.428 1.017 19.11 < 0.0001  
Time  -0.485 0.119 -4.09 < 0.0001 
Intervention  -4.618  0.953 -4.84 < 0.0001 
Time after intervention  0.073  0.155 0.47 0.6419  
b. Most parsimonious segmented 
regression model 
    
Intercept 19.081 0.744 25.64 < 0.0001 
Time -0.437 0.055 -7.94 < 0.0001 
Intervention -4.598 0.941 -4.88 < 0.0001 
 
Using results from Table VIb, we estimated the relative change in utilization was -
90.21%, indicating that utilization of rosiglitazone decreased by 90.21% at the end of the study 
period (month 32) in the contraindicated group compared to what it would have been in the same 
month had the safety warning not been issued. 
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Effect of the FDA safety warning on pioglitazone utilization in appropriate-use patients 
These results (Table VIIa) indicate that just before the beginning of the observation 
period, the utilization rate of pioglitazone in patients deemed appropriate to use any type of 
thiazolidinedione was 16.46 patients per 100 patients per month. Before the warning, there was a 
significant month-to-month utilization increase of 0.744 patients per 100 appropriate-use 
patients. Immediately after the warning, there was no significant change in the utilization of 
pioglitazone (p-value = 0.2869). Following the intervention, there was a significant and 
consistent month-to-month decline of 0.561 patients per 100 appropriate-use patients using 
piogliatzone in comparison to the pre-intervention period.  
 
Table VII: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models of the monthly utilization rate of pioglitazone 
in appropriate-use patients. 
 
Variable  Estimate Standard 
Error  
t-
statistic 
P-value  
a. Full segmented regression model     
Intercept  16.455  1.433 11.48 < 0.0001 
Time  0.744  0.161 4.61 < 0.0001  
Intervention  1.247  1.148 1.09 0.2869  
Time after intervention  -0.561 0.220 -2.56 < 0.0001 
b. Most parsimonious segmented 
regression model 
    
Intercept 16.286 1.539 10.59 < 0.0001
Time 0.805 0.163 4.93 < 0.0001
Time after intervention -0.583 0.236 -2.47 0.0198 
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From Table VIIb, we further estimated a relative change in utilization of -26.34%, indicating that 
the utilization of pioglitazone in the appropriate-use group decreased by 26.34% at the end of the 
study period (month 32) compared to what it would have been in the same month had the safety 
warning not been issued. 
 
Effect of the FDA safety warning on pioglitazone utilization in patients at risk of 
developing contraindicated conditions 
The pre-observation utilization rate of pioglitazone in the at risk group was 20.85 patients 
per 100 patients per month. There was a significant month-to-month increase of 0.642 patients 
per 100 patients per month in the utilization rate within this group. There was however no 
significant effect of the safety warning on the use of pioglitazone immediately after the safety 
warning (p-value = 0.2534). Following the intervention, the use of pioglitazone decreased at a 
rate of 0.845 patients per 100 patients per month (Table VIII). 
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Table VIII: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models of the monthly utilization rate of pioglitazone 
in patients at-risk of developing contraindicated conditions. 
 
Variable  Estimate Standard 
Error  
t-
statistic 
P-value  
a. Full segmented regression model     
Intercept  20.850 1.490 13.99 < 0.001  
Time  0.642 0.165 3.90 < 0.001  
Intervention  1.287 1.103 1.17 0.2534 
Time after intervention  -0.845 0.228 -3.71 < 0.001  
b. Most parsimonious segmented 
regression model 
    
Intercept 20.707 1.499 13.81 < 0.001 
Time 0.699 0.159 4.40 < 0.001 
Time after intervention -0.853 0.230 -3.72 < 0.001 
 
From Table VIIIb, we estimated a relative change in utilization of -37.63%, indicating 
that piogliatzone utilization rate in the at risk group decreased by 37.63% at the end of the study 
period (month 32) compared to what it would have been in the same month had the safety 
warning not been issued. 
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Effect of the FDA safety warning on pioglitazone utilization in rosiglitazone-
contraindicated patients 
In the period just before the observation period, the monthly utilization rate of 
pioglitazone in the patient population identified as contraindicated for rosiglitazone use was 
24.79 patients per 100 patients. Before the intervention, there was a significant month-to-month 
decline of 0.45 patients per 100 patients in pioglitazone utilization. In the period immediately 
following the intervention, there was no significant change in the rate of pioglitazone use (p-
value = 0.1222). There was also no significant month-to-month change in the utilization rate of 
pioglitazone after the safety warning (p-value = 0.8030) (Table IXa). 
 
Table IX: Parameter estimates, standard errors and P-values from the full and most 
parsimonious segmented regression models of the monthly utilization rate of pioglitazone 
in contraindicated patients. 
 
Variable  Estimate Standard 
Error  
t-
statistic 
P-value  
a. Full segmented regression model     
Intercept  24.790 0.670 36.99 < 0.001  
Time  -0.450 0.828 -5.43 < 0.001   
Intervention  -1.222 0.766 -1.60 0.1222 
Time after intervention  0.025 0.099 0.25 0.8030 
b. Most parsimonious segmented 
regression model 
    
Intercept 24.856 0.554 44.84 < 0.001 
Time -0.487 0.029 16.83 < 0.001 
There was no relative change in pioglitazone utilization within this group since there was 
no absolute effect of the safety warning on drug utilization in this group.
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CHAPTER V 
DISCUSSION 
In this study, we analyzed the rate (percentage utilization) of rosiglitazone and 
pioglitazone use among three patient groups (appropriate-use, at risk and contraindicated groups) 
using a national sample of Medicare during the 13 months before and 19 months following the 
FDA safety warning about the use of rosiglitazone. The inclusion of the pioglitazone group 
allowed for assessment of possible class effects of the safety warning.  
Findings from this study suggest that the initial safety warning was adequate in reducing 
the utilization of rosiglitazone in the population targeted by the warning, as well as the other 
non-targeted groups. The warning however, did not produce significant reductions, immediate or 
sustained, in the percentage of patients considered to be contraindicated and on pioglitazone. 
Similarly, the warning had no significant effect in reducing utilization of pioglitazone in other 
groups in the period immediately after the safety warning. These findings signify that the initial 
safety warning only had an immediate effect in the group targeted by the warning. Our findings, 
are thus contrary to previous findings on the overall effects of safety warnings specific to 
rosiglitazone and troglitazone  observed by Shah et al.10 and Wilkinson et al.11 Both studies 
demonstrated that initial safety warnings were inadequate in reducing utilization of respective 
drugs.
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We also observed that during the pre-intervention period, the average monthly utilization 
of pioglitazone was 20.7 patients per 100 patients, marginally surpassing that of rosiglitazone 
(19.63 patients per 100 patients). We attributed this finding to prior sensitization of the medical 
and general community to the safety concerns raised about rosiglitazone use during the pre-
warning period. Similar assumptions about the insignificant effects of the safety warning in the 
at risk patient group using rosiglitazone as well as the appropriate-use and at risk groups using 
pioglitazone can be made because despite an noticeable decline in slope for percentage 
utilization of rosiglitazone and an increasing slope for percentage utilization of pioglitazone, the 
effects of the safety warning was insignificant in these groups.  
In the appropriate-use group, we estimated that at the end of the study period (month 32), 
the relative utilization rates of rosiglitazone and pioglitazone decreased significantly by 74.78% 
and 26.34% respectively in comparison to expected utilization rates in the absence of the safety 
warning, indicating that the safety warning had spillover effects in this group for both drugs.  
Similar findings, demonstrated by significant post-intervention decline in drug use in the at risk 
groups of both drugs were observed. Our findings in this regard supports the findings of Katz et 
al.8 who demonstrated spillover effects of safety warnings to populations not targeted by such 
warnings.  
A secondary effect of implementing a safety warning such as this is, as suggested by 
Wilkinson et al,11 is a reduction in the frequency of utilization of the implicated drug.  Our 
findings also demonstrate this secondary effect as we observed a general decline in rosiglitazone 
utilization across all patient groups using rosiglitazone following the safety warning. During the 
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pre-intervention period, rosiglitazone and pioglitazone use accounted for almost equal shares of 
the thiazolidinedione market within our study population (accounting for an average of 50.95% 
and 49.05% of the market share respectively). Following the intervention, market share reduced 
drastically in the rosiglitazone drug group to 26.66% but increased considerably in the 
pioglitazone group to 73.34%. Furthermore, the reduction in rosiglitazone utilization at the end 
of the study relative to the expected utilization rate in the absence of the intervention, in the 
appropriate-use, at-risk and contraindicated patients were 74.78%, 79.93% and 90.21% 
respectively. Likewise, we estimated reductions of 26.34% and 37.63% in the utilization of 
piogliatzone for appropriate-use and at risk patient groups respectively. These support the 
findings of various investigators who have identified the effects of regulatory warnings on drug 
utilization. Katz et al. demonstrated a general decline in prescription rates and therefore use of 
antidepressants following the Health Canada warning. Similarly, Wilkinson et al. and Shah et al. 
reported decreased utilization of troglitazone and rosiglitazone respectively following safety 
warnings, however in the case of rosiglitazone the declining use varied geographically.  
Over the duration of the study, the market differentiation amongst appropriate-use, at risk 
patients and contraindicated patients varied considerably between rosiglitazone and pioglitazone 
group. During the pre-intervention period, there was minimal differentiation in utilization rates 
among all patient subgroups. Before the safety warning, the average difference in utilization 
rates between appropriate-use and contraindicated use was 6.7% and -0.2% for rosiglitazone and 
pioglitazone respectively.  Following the intervention, the average difference was 6.8% and 
16.30% respectively. This difference, seen with pioglitazone utilization, is an indication of 
appropriate differentiation of drug use among appropriate-use and contraindicated patient 
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groups. The same, on the other hand, was not evident with rosiglitazone. From a market 
perspective, the importance of this patient differentiation in minimizing risks associated with 
drug use in the event of a safety warning cannot be over emphasized. The significant decrease in 
utilization rates of pioglitazone in the appropriate and at-risk patient groups (-0.583 (p-value = 
0.0198) and -0.853 patients per 100 patients (p-value = 0.0009) respectively) after the warning 
resulted in 26.34% and 37.63% decrease in pioglitazone utilization in respective groups at the 
end of the study period compared to expected utilization rates in the same month had the policy 
not been implemented, despite insignificant immediate effects of the safety warning in these 
groups could be attributed in part to a “class effect” of the safety warning. We also attributed this 
finding to the numerous risk management and marketing efforts employed by Takeda 
pharmaceuticals in the wake of the rosiglitazone safety warnings.  
The differential effects of the safety warning on thiazolidinedione utilization observed in 
our study could be attributed to the fact that our study methods took classification of patients 
based on their potential drug-use risk profile into consideration. Moreover, the study design, 
which is the strongest, quasi-experimental design for evaluating longitudinal effects of time-
delimited interventions28 as well as the statistical analysis method employed enabled the 
identification of the immediate and sustained effects of interventions through analysis of change 
in level and slope pre- and post-intervention.28,29 We could thus adequately differentiate between 
the immediate and sustained effects of the safety warnings. 
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Study Limitations 
This study evaluated the utilization of rosiglitazone and pioglitazone in the Medicare 
population in light of the safety warning for rosiglitazone; hence the results of the study are only 
generalizable to the Medicare population. Secondly, since this study relied on following a 
consistent cohort through the entire duration of the study, we could not determine the overall use 
pattern of thiazolidinediones during this period. Lastly, the media focus on rosiglitazone safety 
concerns prior to the FDA safety warning might have confounded the effects observed. 
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CHAPTER VI  
CONCLUSIONS 
The initial safety warning issued by the FDA about an ongoing safety review of 
rosiglitazone’s potential to increase cardiovascular risks was effective in decreasing the 
utilization of the implicated drug in the targeted population and hence rosiglitazone market share 
within the Medicare thiazolidinedione market. There was no obvious differentiation in 
rosiglitazone use among different patient groups in response to the safety warning. Similarly, the 
safety warning had spillover effects, reducing utilization of drugs in other patient cohorts not 
targeted by the warning, an indication that the response to the safety warning might have been 
inappropriate in these groups. There was also an in-class shift in thiazolidinedione utilization 
from rosiglitazone to pioglitazone despite a “class effect”. We thus conclude that the Medicare 
thiazolidinedione market responded promptly and appropriately to the May 2007 FDA safety 
warning for rosiglitazone resulting in a significant decline in rosiglitazone utilization in the 
targeted cohort and a general reduction in rosiglitazone market share across patient groups. 
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